Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Vasoactive intestinal peptide is a neuroprotective factor that has a stimulatory effect on the growth of some tumor cells and an inhibitory effect on others. Additionally we are shipping Activity-Dependent Neuroprotector Homeobox Kits (7) and Activity-Dependent Neuroprotector Homeobox Proteins (3) and many more products for this protein.
Showing 10 out of 94 products:
Chicken Polyclonal ADNP Primary Antibody for WB - ABIN2780972
Mandel, Gozes: Activity-dependent neuroprotective protein constitutes a novel element in the SWI/SNF chromatin remodeling complex. in The Journal of biological chemistry 2007
Human Polyclonal ADNP Primary Antibody for ICC, IF - ABIN258198
Cattano, Valleggi, Ma, Kastsiuchenka, Abramo, Sun, Cavazzana, Natale, Maze, Giunta: Xenon induces transcription of ADNP in neonatal rat brain. in Neuroscience letters 2008
Human Polyclonal ADNP Primary Antibody for ELISA, WB - ABIN1534122
Deloukas, Matthews, Ashurst, Burton, Gilbert, Jones, Stavrides, Almeida, Babbage, Bagguley, Bailey, Barlow, Bates, Beard, Beare, Beasley, Bird, Blakey, Bridgeman, Brown, Buck, Burrill, Butler, Carder et al.: The DNA sequence and comparative analysis of human chromosome 20. ... in Nature 2002
Hippocampal ADNP expression was greater in males than in females. Haploinsufficiency led to increased hippocampal eIF4E and ApoE expression.
the newly identified shared microtubule target of NAP (show CTNNBL1 Antibodies)/ADNP is directly implicated in synaptic plasticity, explaining the breadth and efficiency of neuroprotective/neurotrophic capacities
ADNP expression is increased in the cerebral cortex of a transgenic mouse model of Alzheimer disease.
NAP (show CTNNBL1 Antibodies) is an ADNP derived peptide that modulates the tubulin (show TUBB Antibodies) pool in mice and rats
Results support the hypothesis that ADNP expression is related to early or mild Alzheimer's disease progression by a VIP (show Vip Antibodies)-independent mechanism.
ADNP is identified as a new key gene essential for organogenesis in the developing embryo and may be implicated as a clinical target associated with proper neurodevelopment.
ADNP has a part in the estrus cycle as an affecter or an effector.
The mRNA transcripts for activity-dependent neuroprotective protein (ADNP, the NAP (show CTNNBL1 Antibodies) containing protein) were shown to increase 29 days post closed head injury in the injured hemisphere of Mac-1 (show ITGAM Antibodies) expressing mice.
ADNP expression is mediated through multiple receptors and signaling pathways that are regulated by different concentrations of PACAP (show ADCYAP1 Antibodies)
results place ADNP at a crucial point of gene regulation, repressing potential endoderm genes and enhancing genes associated with organogenesis/neurogenesis
This review covers the myriad of important ADNP-protein interactions and glimpse at their potential meaning in autism, schizophrenia and Alzheimer's disease. [review]
ADNP expression was increased in male hippocampus samples compared to female samples.
Mutations in the ADNP gene cause syndromic autism.Ample evidence exists that ADNP is of key importance for proper functioning of the nBAF complex.
This study showed ADNP that deregulated in postmortem hippocampal samples from schizophrenia patients, but that now showed a significantly increased expression in lymphocytes from related patients.
Ten patients with autism spectrum disorders and other shared clinical characteristics, including intellectual disability and facial dysmorphisms caused by a mutation in ADNP, a transcription factor involved in the SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) remodeling complex.
Chromatin immunoprecipitation demonstrates the ability of ADNP to bind to its own promoter, consistent with its action as a repressor of both promoter-supported and endogenous ADNP expression.
Our results suggested that ADNP may play an important role in slowing the progression of clinical symptoms of AD.
In the prefrontal cortex of schizophrenia patients the correlation between ADNP and ADNP2 (show ADNP2 Antibodies) mRNA levels was apparently higher than in the hippocampus (r=0.854, p<0.001), but did not reach a significant difference (p=0.25).
ADNP is expressed in many immune system cells. ADNP mRNA is reduced in PBMCs in MS. The peptide NAP (show CTNNBL1 Antibodies), which plays an important role in neuroprotection, has potential immunomodulatory properties.
Activity-dependent neuroprotective protein constitutes a novel element in the SWI (show SMARCA1 Antibodies)/SNF (show SNRPA Antibodies) chromatin remodeling complex.
Vasoactive intestinal peptide is a neuroprotective factor that has a stimulatory effect on the growth of some tumor cells and an inhibitory effect on others. This gene encodes a protein that is upregulated by vasoactive intestinal peptide and may be involved in its stimulatory effect on certain tumor cells. The encoded protein contains one homeobox and nine zinc finger domains, suggesting that it functions as a transcription factor. This gene is also upregulated in normal proliferative tissues. Finally, the encoded protein may increase the viability of certain cell types through modulation of p53 activity. Alternatively spliced transcript variants encoding the same protein have been described.
activity-dependent neuroprotector homeobox protein
, ADNP homeobox 1
, activity-dependent neuroprotective protein
, NAP peptide